PHARMAEUT1CAL company Claris Life-sciences l.td has entered into a strategic alliance with the1.4 billion Danish Kroner firm Copyfarm for marketing its products in Finland. Claris received the good manufacturing practices (GMP} approval from Finland regulatory authority, a senior company executive told ET today.
The company is expecting a market share of close to 3.56 million euros from its products in the 1,571 million euro Finland market. With this approval, Claris is looking at marketing its bestseller anesthetic, Propofol intravaneous injection, along with high-end anti-infectives such as ciprofloxacin and metronidazole in the Finnish market.
Claris said that it also gearing up to introduce a couple of more specialty critical-care products in the near future.
Claris Lifesciences has expertise in manufacturing and marketing injectables products. The company's range of products and delivery systems extends across enteral and parenteral nutrition, anaesthesia, blood products and plasma volume expanders, anti infectives, dialysis and transplant, cardiac care,